Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management

  title={Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management},
  author={Donald C. Moore and Annie Pellegrino},
  journal={Annals of Pharmacotherapy},
  pages={797 - 803}
Objective: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). Data Sources: PubMed was searched from 1980 to March 31, 2017, using the terms pegfilgrastim and bone pain. Study Selection and Data Extraction: English-language, human studies and reviews assessing the incidence, risk factors, and management of PIBP were incorporated. Data Synthesis: A total of 3 randomized, prospective studies and 2 retrospective studies evaluated pharmacological… 

Tables from this paper

Efficacy of “Naproxen and Loratadine” Versus “Acetaminophen and Loratadine” on Relief of Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF)-Induced Bone Pain During Chemotherapy; A Randomized Controlled Trial

By controlling the effects of age, sex, and baseline pain, Naproxen in the second and subsequent courses of treatment was significantly better than Acetaminophen in reducing pain.

Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.

Oral loratadine was found to be associated with pain reduction in patients with cancer receiving G-CSFs, and it was found that bone pain induced by granulocyte-colony stimulating factors can be alleviated or eliminated by oral antihistamine lor atadine.

Neurophysiological Mechanisms Related to Pain Management in Bone Tumors

Cancer-induced bone pain could include neuropathic and inflammatory pain, but with different modifications to the periphery tissue, nerves and neurochemical changes in different neurological levels, and opportunity areas in pharmacological and non-pharmacological pain management are explored.

Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study

The results from this post-marketing surveillance study support the safety and effectiveness of PegaGen® used for the prevention of chemotherapy-induced FN in patients with various types of cancer and treatment regimens.

Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?

Although more research is needed, loratadine's tolerability, ease of administration, and potential benefit mean that it should be considered for management of pegfilgrastim-associated bone pain.

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database

It is demonstrated that the occurrence of bone pain was similar with FIL and PEG-F, and the incidence of neutropenia and febrile neutropania was higher in FIL compared to P EG-F.

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim, and bone pain reduction, thrombocytopenia reduction, and quality of life maintenance will be secondary end points.

Title Oral loratadine in the management of G-CSF induced bone pain: a pilot study

Oral loratadine in the management of G-CSFinduced bone pain: a pilot study.

Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study

The combination therapy with Peg G and mFFX markedly prolonged the progression-free survival compared with the non-Peg G group, and its effects were associated with a reduced incidence of neutropenic events as well as lower rates of dosage reduction, delayed chemotherapy due to neutropic events and altered blood cell counts after chemotherapy.

Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.

Convenience, effectiveness, and safety of prophylaxis for FN in the prospective pegfilgrastim group were significantly improved compared to the retrospective filgrastic group in ASCT patients, especially for MM patients.



Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients

Pegfilgrastim is commonly used for primary prophylaxis during the first cycle of chemotherapy, and loratadine was the most commonly employed medication to mitigate this adverse effect.

Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim

Administration of prophylactic loratadine does not decrease the incidence of severe bone pain or improve quality of life in a high-risk patient population.

Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

It is demonstrated that naproxen at a dose of 500 mg twice per day is effective in reducing the incidence and severity of pegfilgrastim-induced bone pain.

Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report

  • C. RomeoQuan-wang LiL. Copeland
  • Medicine
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2015
The first case report in which loratadine prophylaxis completely alleviated NSAID-resistant severe pain secondary to pegfilgrastim is presented, showing that lor atadine may be a promising option for severe, resistant pegfilGrastim-induced bone pain.

Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

Potential risk factors for bone pain in patients receiving myelosuppressive chemotherapy and primary prophylactic pegfilgrastim identified in this study are younger age and history of bone pain.

Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy

Empiric dose reduction from 6mg to 4mg administered on the day after chemotherapy was used to ameliorate pain while maintaining count recovery in patients who had empiric dose reductions because of bone pain with concomitant normal or high leukocyte counts during recovery.

Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade

The use of a double histamine blockade is an inexpensive, safe, and effective way to alleviate bone pain symptoms secondary to G-CSF agents.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

All dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.

Nolan: A randomized, phase II study to estimate the effect of prophylactic naproxen (N) or loratadine (L) vs no intervention on bone pain in 600 patients (pts) with early-stage breast cancer receiving chemotherapy (chemo) and pegfilgrastim (PEG).

Mild-to-moderate bone pain is the most commonly reported adverse event associated with PEG and N (an NSAID) and L (an antihistamine) are used in the clinic to reduce this AE.